Anna Guillen-Sola’s work focuses on translational research in neurological rehabilitation, particularly in the dysphagia field. She has a more than 15 years of experience in neurogenic dysphagia and stroke. Her research basically focuses on dysphagia in the stroke population, how to perform a good diagnostic and new techniques to treat swallowing disturbances. In the Neuromuscular field, the collaboration in two projects can be highlighted: 1) to identify clinical biomarkers of bulbar dysfunction in ALS patients and 2) to evaluate muscle training for the management of dysphagia in patients with myasthenia gravis and mitochondrial myopathy. She has also participated as a co-Investigator on a few funded grants for research in stroke patients. Her other fields of interest are neuromuscular diseases, head and neck cancer patients, and sarcopenia. In addition, she has successfully collaborated with other researchers, and contributed to several peer-reviewed publications.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.